{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:26:57Z","timestamp":1787023617521,"version":"build-2736575974"},"reference-count":55,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,6,25]]},"DOI":"10.18632\/oncotarget.27010","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T08:51:02Z","timestamp":1561452662000},"page":"4125-4138","source":"Crossref","is-referenced-by-count":14,"title":["Transcriptional suppression of the miR-15\/16 family by c-Myc in malignant pleural mesothelioma"],"prefix":"10.18632","volume":"10","author":[{"given":"Marissa","family":"Williams","sequence":"first","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Yee","family":"Cheng","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela B.","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir H.","family":"Sarun","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schelch","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Winata","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McCaughan","sequence":"additional","affiliation":[{"name":"PAH Medical Centre, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"},{"name":"Chris O'Brien Lifehouse, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Van Zandwijk","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Reid","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, Sydney, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/jco.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Kindler","year":"2009","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1158\/0008-5472.can-09-1298","article-title":"Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells","volume":"69","author":"Sarkar","year":"2009","journal-title":"Cancer Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","article-title":"Chemotherapy and targeted therapies for unresectable malignant mesothelioma","volume":"73","author":"Hassan","year":"2011","journal-title":"Lung Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"Lundgren","year":"2010","journal-title":"Lung Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","article-title":"Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis","volume":"174","author":"Bosari","year":"2009","journal-title":"Am J Pathol"},{"key":"6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(17)30191-2","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma","volume":"18","author":"Mantovani","year":"2017","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Chen","year":"2016","journal-title":"Sci Transl Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00262-018-2191-3","article-title":"Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge","volume":"67","author":"Maio","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Kim","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Lund","year":"2012","journal-title":"Mol Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.molcel.2009.10.006","article-title":"Hormonal Regulation of MicroRNA Biogenesis","volume":"36","author":"C\u00e1ceres","year":"2009","journal-title":"Mol Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Croce","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Golub","year":"2005","journal-title":"Nature"},{"key":"14","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Pass","year":"2011","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Brahmbhatt","year":"2013","journal-title":"Ann Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3978\/j.issn.2072-1439.2015.04.56","article-title":"MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis"},{"key":"17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/2211536605666161208154633","article-title":"Exploring Mechanisms of MicroRNA Downregulation in Cancer","volume":"6","author":"Reid","year":"2017","journal-title":"Microrna"},{"key":"18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.lungcan.2013.09.017","article-title":"The degree of microRNA-34b\/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma","volume":"82","author":"Tsukuda","year":"2013","journal-title":"Lung Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"22809","DOI":"10.1074\/jbc.M110.100354","article-title":"Pro-tumorigenic effects of miR-31 loss in mesothelioma","volume":"285","author":"Pass","year":"2010","journal-title":"J Biol Chem"},{"key":"20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"van Zandwijk","year":"2016","journal-title":"Epigenomics"},{"key":"21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/1078-0432.ccr-11-2450","article-title":"Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers","volume":"18","author":"Klepetko","year":"2012","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1038\/onc.2011.62","article-title":"MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia","volume":"30","author":"Yu","year":"2011","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"publisher","first-page":"23480","DOI":"10.18632\/oncotarget.4346","article-title":"miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma","volume":"6","author":"Cooper","year":"2015","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Mendell","year":"2008","journal-title":"Nat Genet"},{"key":"25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/onc.2014.82","article-title":"c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2\u03b1 and promotes tumor angiogenesis and metastasis by upregulating FGF2","volume":"34","author":"Sun","year":"2014","journal-title":"Oncogene"},{"key":"26","doi-asserted-by":"publisher","first-page":"e0138560","DOI":"10.1371\/journal.pone.0138560","article-title":"c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line","volume":"10","author":"Tsumura","year":"2015","journal-title":"PLoS One"},{"key":"27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/JTO.0000000000000202","article-title":"Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma","volume":"9","author":"Wistuba","year":"2014","journal-title":"J Thorac Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/s0960-9822(03)00297-5","article-title":"Analysis of Myc bound loci identified by CpG is land arrays shows that Max is essential for Mycdependent repression","volume":"13","author":"Penn","year":"2003","journal-title":"Curr Biol"},{"key":"29","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Croce","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"30","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Negrini","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1073\/pnas.0508889103","article-title":"microRNAs exhibit high frequency genomic alterations in human cancer","volume":"103","author":"Katsaros","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1158\/0008-5472.Can-08-4277","article-title":"miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer","volume":"69","author":"Vassella","year":"2009","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jcp.20282","article-title":"miR-15a and miR-16-1 down-regulation in pituitary adenomas","volume":"204","author":"degli Uberti","year":"2005","journal-title":"J Cell Physiol"},{"key":"34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Croce","year":"2012","journal-title":"EMBO Mol Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00428-010-1030-5","article-title":"Frequent concomitant inactivation of miR-34a and miR-34b\/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas","volume":"458","author":"Hermeking","year":"2011","journal-title":"Virchows Arch"},{"key":"36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2012-07-444729","article-title":"Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN\/PI3K signal pathway","volume":"121","author":"Jiang","year":"2013","journal-title":"Blood"},{"key":"37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7150\/thno.22377","article-title":"Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK\/ERK pathways","volume":"8","author":"Chan","year":"2018","journal-title":"Theranostics"},{"key":"38","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","article-title":"Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia","volume":"119","author":"Keating","year":"2012","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/onc.2011.470","article-title":"Myc represses miR-15a\/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas","volume":"31","author":"Tao","journal-title":"Oncogene"},{"key":"40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1478-811X-7-18","article-title":"Regulation of MicroRNA Biogenesis: A miRiad of mechanisms","volume":"7","author":"Hata","year":"2009","journal-title":"Cell Commun Signal"},{"key":"41","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1158\/0008-5472.can-05-2352","article-title":"A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation","volume":"65","author":"Takahashi","year":"2005","journal-title":"Cancer Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Scherr","year":"2007","journal-title":"Blood"},{"key":"43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas","volume":"22","author":"Seto","year":"2012","journal-title":"Cancer Cell"},{"key":"45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/sj.onc.1207225","article-title":"Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product","volume":"23","author":"Kretzner","year":"2004","journal-title":"Oncogene"},{"key":"46","first-page":"51","article-title":"Mechanisms of transcriptional repression by Myc","volume":"302","author":"Eilers","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1476-4598-9-92","article-title":"Myc interacts with Max and Miz1 to repress C\/EBP\u03b4 promoter activity and gene expression","volume":"9","author":"DeWille","year":"2010","journal-title":"Molecular Cancer"},{"key":"48","doi-asserted-by":"publisher","first-page":"a014290","DOI":"10.1101\/cshperspect.a014290","article-title":"The Role of MIZ-1 in MYC-Dependent Tumorigenesis","volume":"3","author":"Eilers","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/cdd.2009.69","article-title":"miR-15a and miR-16-1 in cancer: discovery, function and future perspectives","volume":"17","author":"Croce","year":"2010","journal-title":"Cell Death Differ"},{"key":"50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Felsher","year":"2016","journal-title":"Science"},{"key":"51","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma","volume":"12","author":"Boyer","year":"2017","journal-title":"J Thorac Oncol"},{"key":"52","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/jcmm.12882","article-title":"MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation","volume":"20","author":"Wang","year":"2016","journal-title":"J Cell Mol Med"},{"key":"53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2017.06.006","article-title":"MYC expression correlates with PD-L1 expression in non-small cell lung cancer","volume":"110","author":"Chang","year":"2017","journal-title":"Lung Cancer"},{"key":"54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"55","first-page":"321","article-title":"Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase","volume":"5","author":"Watson","year":"2009","journal-title":"Journal of RNAi and Gene Silencing : An International Journal of RNA and Gene Targeting Research"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T14:47:24Z","timestamp":1596725244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":55,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2019,6,25]]}},"alternative-id":["27010","31289611"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27010","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]}}}